The startup develops glioblastoma-specific drugs through the detection and selection of therapeutic molecules, followed by research-grade production and cGMP manufacturing. This approach enables healthcare professionals to effectively treat glioblastoma multiforme, a highly aggressive brain tumor with limited treatment options.
Funding
$2.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Glioblastoma multiforme (GBM) is an aggressive brain tumor with limited effective treatment options, resulting in poor patient outcomes. Current therapeutic approaches often fail to adequately address the complex nature of GBM and its resistance to conventional therapies. There is a need for novel therapeutic molecules that can effectively target GBM cells while also protecting healthy brain tissue.
Solution
GlioCure is a drug development company specializing in neuro-oncology, focused on discovering and developing novel therapeutic molecules for glial diseases, particularly brain tumors like glioblastoma. The company offers a translational solution for transforming molecules of interest into drug candidates, involving the detection, selection, pharmacological development, and pharmaceutical development of these molecules. GlioCure's lead product, GC01.1, is a new-generation anti-tumor and neuroprotective peptide currently in the final stages of non-regulatory preclinical development. GC01.1 exhibits a dual mechanism of action, inhibiting tumor cell division and promoting neuroprotection through the differentiation of neural stem cells.
Target Audience
GlioCure's primary target audience includes healthcare professionals, particularly neuro-oncologists, seeking more effective treatments for glioblastoma and other glial-related diseases, as well as patients and families affected by these conditions.
Features
- GC01.1: A synthetic peptide with both anti-tumor and neuroprotective activities.
- Inhibition of tumor cell division.
- Induction of neural stem cell differentiation for neuroprotection.
- Focus on glioblastoma and other solid tumors overexpressing βIII-tubulin.
- Complete translational solution from molecule discovery to clinical trial readiness.